Core Insights - Longevity Health Holdings, Inc. (XAGE) focuses on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition [2] - The company announced a merger agreement with 20/20 BioLabs, which will continue as a wholly owned subsidiary post-merger [4] Business Updates - 20/20 develops laboratory tests for early detection and management of chronic disease risk, including a multi-cancer early detection blood test and a new blood test for monitoring chronic inflammation [1][4] - XAGE reported Q1 sales of approximately $663,000, an 8% increase year-over-year, while 20/20 reported sales of approximately $562,000, a 15% increase year-over-year [4] - A reverse stock split of 1 for 30 was completed on May 12, 2025, with trading at the adjusted price starting on May 14, 2025 [4] Product Launches - XAGE plans to launch a medicated cleanser for use in physicians' offices and MedSpas, targeting 20/20's customer base [4] - 20/20 is set to launch a lab test measuring inflammatory biomarkers, which will also be marketed to XAGE's customer base [4] - An initiative with Giant Food will offer 20/20's multi-cancer test in select stores, with potential expansion to include tests for biomarkers linked to pro-inflammatory foods [4] Financial Considerations - XAGE is evaluating options for additional financing and anticipates announcing a primary investment in Q2 2025 [4]

Core Viewpoint - Longevity Health Holdings, Inc. has announced a merger with 20/20 BioLabs, Inc. in an all-stock transaction aimed at enhancing its diagnostics capabilities and addressing chronic disease risks in America [1][4]. Company Overview - Longevity Health Holdings focuses on human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition [1][10]. - 20/20 BioLabs specializes in laboratory tests for early detection and management of chronic disease risk, offering the only multi-cancer early detection blood test available for under $200 [9][10]. Merger Details - The merger is expected to close in the third quarter of 2025, pending customary closing conditions and stockholder approvals [7]. - Post-merger, 20/20 stockholders will own approximately 50.1% and Longevity stockholders will own approximately 49.9% of the combined company [7]. - The combined company will continue trading on Nasdaq under the symbol "XAGE" [1]. Financial Implications - The merger is projected to double Longevity's fiscal year 2025 revenue forecast from approximately $3-4 million to approximately $7-8 million [6][7]. - The combined company is expected to have a post-merger equity valuation of approximately $99 million, with 20/20's pre-money valuation at around $50 million [6][7]. - Anticipated operational savings and synergies are expected to exceed $1 million in fiscal year 2025 [6]. Strategic Goals - The merger aligns with Longevity's strategy to expand its footprint in diagnostics and enhance synergies with its existing product portfolio [1][4]. - The combined company aims to address the epidemic of chronic disease in America under the "Healthy Aging, Inside and Out™" initiative [1]. Management Structure - The management team of the combined company will be mutually selected, with a Board of Directors comprising three members from each company [8].

As filed with the Securities and Exchange Commission on September 28, 2023 Registration No. 333-______________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Elevai Labs, Inc. (Exact name of registrant as specified in its charter) Not Applicable (Translation of Registrant's Name into English) (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code ...